Movement Alert|Axsome Therapeutics Intraday Decline 4.16%, prior post-earnings re-rating cools after recent Q3-driven rally

Market Focus11-13

On November 13, Axsome Therapeutics fell 4.16% in Regular Trading, trading at $138.51 per share, with turnover of $6.5193 million.

The move came as the market cooled on the company’s recent post-earnings re-rating after several sessions of gains tied to stronger-than-expected third-quarter results and improving visibility toward a potential profitability inflection.

Earlier disclosures showed third-quarter EPS of negative $0.25, better than expectations of roughly negative $0.56 to negative $0.63, while revenue reached $259.7 million versus expectations near $249 million. Auvelity net product sales were $207.6 million, and recent analyst commentary indicated Axsome Therapeutics could achieve earnings in 2027 as losses narrow and Auvelity grows, though the ramp of the Alzheimer’s disease agitation indication remains under watch.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment